Merus (NASDAQ:MRUS) Upgraded at BidaskClub
Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Merus from a buy rating to a hold rating in a research note on Saturday, August 10th. Roth Capital initiated coverage on shares of Merus in a research report on Friday, June 28th. They set a buy rating and a $20.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Merus presently has an average rating of Buy and an average price target of $22.57.
NASDAQ MRUS opened at $15.77 on Wednesday. Merus has a 12 month low of $11.00 and a 12 month high of $22.40. The company’s 50 day moving average is $15.76 and its two-hundred day moving average is $14.14.
Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 2,373 shares during the last quarter. Morgan Stanley raised its position in shares of Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 2,788 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 3,389 shares during the last quarter. Athanor Capital LP bought a new stake in shares of Merus during the second quarter valued at approximately $334,000. Finally, Artal Group S.A. raised its position in shares of Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after buying an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 52.39% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Further Reading: How mutual funds make money
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.